EHMT2 and ovarian carcinoma: Clinicopathologic associations of EHMT2, a transcriptional repressor that methylates H3K9 and H3K27, have been reported in NSCLC, gastric cancer, hepatocellular carcinoma (HCC), ovarian cancer, and SCCHN.